Lumos Pharma Statistics
Total Valuation
Lumos Pharma has a market cap or net worth of $37.54 million. The enterprise value is $24.19 million.
| Market Cap | 37.54M |
| Enterprise Value | 24.19M |
Important Dates
The last earnings date was Thursday, November 7, 2024.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lumos Pharma has 8.65 million shares outstanding. The number of shares has decreased by -0.71% in one year.
| Current Share Class | 8.65M |
| Shares Outstanding | 8.65M |
| Shares Change (YoY) | -0.71% |
| Shares Change (QoQ) | +2.65% |
| Owned by Insiders (%) | 13.90% |
| Owned by Institutions (%) | 24.15% |
| Float | 5.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.06 |
| Forward PS | n/a |
| PB Ratio | 7.64 |
| P/TBV Ratio | 7.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.66, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.66 |
| Quick Ratio | 2.11 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -172.83% and return on invested capital (ROIC) is -111.17%.
| Return on Equity (ROE) | -172.83% |
| Return on Assets (ROA) | -69.64% |
| Return on Invested Capital (ROIC) | -111.17% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | $66,818 |
| Profits Per Employee | -$1.06M |
| Employee Count | 33 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +48.63% in the last 52 weeks. The beta is 0.31, so Lumos Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +48.63% |
| 50-Day Moving Average | 4.20 |
| 200-Day Moving Average | 3.09 |
| Relative Strength Index (RSI) | 55.58 |
| Average Volume (20 Days) | 132,961 |
Short Selling Information
The latest short interest is 54,328, so 0.63% of the outstanding shares have been sold short.
| Short Interest | 54,328 |
| Short Previous Month | 89,511 |
| Short % of Shares Out | 0.63% |
| Short % of Float | 0.93% |
| Short Ratio (days to cover) | 0.59 |
Income Statement
In the last 12 months, Lumos Pharma had revenue of $2.21 million and -$34.92 million in losses. Loss per share was -$4.28.
| Revenue | 2.21M |
| Gross Profit | 2.21M |
| Operating Income | -36.33M |
| Pretax Income | -35.75M |
| Net Income | -34.92M |
| EBITDA | -36.31M |
| EBIT | -36.33M |
| Loss Per Share | -$4.28 |
Balance Sheet
The company has $13.52 million in cash and $172,000 in debt, giving a net cash position of $13.35 million or $1.54 per share.
| Cash & Cash Equivalents | 13.52M |
| Total Debt | 172,000 |
| Net Cash | 13.35M |
| Net Cash Per Share | $1.54 |
| Equity (Book Value) | 4.91M |
| Book Value Per Share | 0.57 |
| Working Capital | 10.77M |
Cash Flow
| Operating Cash Flow | -31.67M |
| Capital Expenditures | n/a |
| Free Cash Flow | -31.67M |
| FCF Per Share | -$3.66 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,647.57% |
| Pretax Margin | -1,583.49% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -2,320.79% |
Dividends & Yields
Lumos Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.71% |
| Shareholder Yield | 0.71% |
| Earnings Yield | -93.02% |
| FCF Yield | -84.38% |
Analyst Forecast
The average price target for Lumos Pharma is $9.38, which is 116.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.38 |
| Price Target Difference | 116.13% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 37.55% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Lumos Pharma has an Altman Z-Score of -19.87 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -19.87 |
| Piotroski F-Score | 2 |